Neslihan Aygün Kocabaş

ORCID: 0000-0001-5811-1430
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Carcinogens and Genotoxicity Assessment
  • Glutathione Transferases and Polymorphisms
  • Effects and risks of endocrine disrupting chemicals
  • DNA Repair Mechanisms
  • Pharmacogenetics and Drug Metabolism
  • Anesthesia and Neurotoxicity Research
  • Health, Environment, Cognitive Aging
  • Estrogen and related hormone effects
  • Chemical Safety and Risk Management
  • Anesthesia and Sedative Agents
  • Treatment of Major Depression
  • Metabolomics and Mass Spectrometry Studies
  • Neurotransmitter Receptor Influence on Behavior
  • Toxic Organic Pollutants Impact
  • Bipolar Disorder and Treatment
  • Autism Spectrum Disorder Research
  • Air Quality and Health Impacts
  • Genomics, phytochemicals, and oxidative stress
  • Attention Deficit Hyperactivity Disorder
  • Chemical Reactions and Isotopes
  • Stress Responses and Cortisol
  • Acute Lymphoblastic Leukemia research
  • Pesticide Exposure and Toxicity
  • BRCA gene mutations in cancer
  • Water Quality Monitoring and Analysis

Total (Belgium)
2021-2025

Concawe
2023

Saudi Arabia Basic Industries (Netherlands)
2020

Total (France)
2020

Gazi University
2005-2016

Saudi Arabia Basic Industries (United States)
2016

Université Libre de Bruxelles
2010-2015

Fund for Scientific Research
2010-2015

Hôpital Robert-Debré
2012

Erasmus Hospital
2010

Brain-derived neurotrophic factor (BDNF), a member of the nerve growth family neurotrophins, has pivotal roles in neuronal survival, proliferation, and synaptic plasticity brain. Both clinical pharmacological studies have implicated common single nucleotide polymorphism (SNP) at position 196, Val66Met pathophysiology major depressive disorder (MDD), antidepressant response. However, inconsistent results were found between (rs6265) treatment response phenotypes genetic association studies....

10.1097/yic.0b013e32833d18f8 article EN International Clinical Psychopharmacology 2010-10-16

Catechol-O-methyltransferase (COMT) has been suggested to be involved in the pathogenesis and pharmacological treatment of affective disorders. The nonsynonymous single nucleotide polymorphism (SNP) exon 4 (Val108/158Met; rs4680) influences COMT enzyme activity. Inconsistent results were found between Val158Met (rs4680) response phenotypes genetic association studies. However, haplotype combinations alleles at Val108/158Met SNP with other synonymous SNPs gene region have shown...

10.1097/yic.0b013e328338b884 article EN International Clinical Psychopharmacology 2010-06-16

Structure-based grouping of chemicals for targeted testing and read-across is an efficient way to reduce resources animal usage. For substances unknown or variable composition, complex reaction products, biological materials (UVCBs), structure-based virtually impossible. Biology-based approaches such as metabolomics could provide a solution. Here, 15 steam-cracked distillates, registered in the EU through Lower Olefins Aromatics Reach Consortium (LOA), well six major substance constituents,...

10.1007/s00204-023-03638-6 article EN cc-by Archives of Toxicology 2024-01-24

The 5HT2A (5HTR2A) and 5HT1A receptor (5HTR1A) genes are plausible candidate for major depressive disorders. Two single nucleotide polymorphisms, the rs7997012 in 5HTR2A –1019C/G 5HTR1A, were analyzed 206 patients with Diagnostic Statistical Manual of Mental Disorders, fourth edition disorder. Patients retrospectively characterized clinical response to antidepressant treatment. We found a significant difference allele frequency between resistant nonresistant patients. However, following...

10.1097/yic.0b013e328338bcf4 article EN International Clinical Psychopharmacology 2010-05-07

Head and neck squamous cell carcinoma is the fifth most common cancer type worldwide. Even though it known that important environmental aetiological factors for head (HNC) development are tobacco alcohol, genetic susceptibility also thought to be important. The use of biomarkers chromosomal damage due instability in order predict risk as well identify high-risk individuals imperative. We have investigated patients having HNC (n = 59) their first-degree relatives (FDRs) 34) with a biomarker...

10.1093/mutage/geq101 article EN Mutagenesis 2011-01-19

So far, associations between serotonergic neurotransmission pathways and suicidality have been reported. The aim of our study was to investigate the role genetic polymorphisms gene–gene interactions 5-HTR1A 5-HTR2A gene on suicide risk and/or a personal history attempts. A total 374 major depressive disorder patients, adequately treated with antidepressants for at least 4 weeks, were collected in context European multicentre treatment-resistant depression. We assessed using Mini...

10.1097/yic.0000000000000101 article EN International Clinical Psychopharmacology 2015-11-06

10.1016/s1383-5718(97)00135-6 article EN Mutation Research/Genetic Toxicology and Environmental Mutagenesis 1997-11-01

Gemcitabine and other cytidine antimetabolites require metabolic activation by phosphorylation. Deoxycytidine kinase (DCK) monophosphate (CMPK) catalyze these reactions. We have applied a genotype-to-phenotype strategy to study DCK CMPK pharmacogenomics. Specifically, we resequenced <i>DCK</i> <i>CMPK</i> using 240 DNA samples, 60 each from African-American, Caucasian-American, Han Chinese-American, Mexican-American subjects. observed 28 polymorphisms in <i>CMPK</i>, 33 of which were novel....

10.1124/dmd.108.020925 article EN Drug Metabolism and Disposition 2008-06-12

Cytogenetic biomarkers are most frequently used well-established endpoints in human population studies with their sensitivity for measuring exposure to genotoxic agents. They have an important role as early predictors of cancer risk. Identification individual genotypes metabolic gene polymorphisms helps understand the modulation susceptibility by environmental exposures, such cigarette smoking and other lifestyle factors.To evaluate chemicals, we determined DNA damage related glutathione...

10.1089/gtmb.2012.0038 article EN Genetic Testing and Molecular Biomarkers 2012-08-20
Coming Soon ...